📊 MRVI Key Takeaways
Is Maravai Lifesciences Holdings, Inc.. (MRVI) a Good Investment?
Maravai LifeSciences faces severe fundamental deterioration with revenue declining 28.3% YoY alongside persistent operating losses (-3.3% margin) and negative earnings. While the company maintains substantial cash reserves ($165.9M) and exceptional liquidity ratios, the collapsing revenue, inability to generate operating profits, and high debt burden ($241M) with negative interest coverage (-0.1x) create significant financial stress and solvency concerns.
Fundamentals are deteriorating: revenue is down sharply, gross margin is compressed, and operating losses are significant, driving negative free cash flow. Liquidity is strong enough to fund near‑term operations, but leverage alongside negative interest coverage heightens financial risk if profitability doesn’t recover. Until margins and cash generation improve, the outlook remains unfavorable.
Why Buy Maravai Lifesciences Holdings, Inc.. Stock? MRVI Key Strengths
- Strong cash position of $165.9M provides buffer for operations and debt obligations
- Excellent liquidity metrics with current ratio of 5.91x and quick ratio of 4.96x demonstrate ability to meet short-term obligations
- Healthy gross margin of 51.2% indicates underlying products maintain pricing power despite revenue collapse
- Ample liquidity with high current/quick ratios and $216.9M cash
- Low capex requirements support flexibility
- Meaningful revenue base that could benefit from operating leverage if demand stabilizes
MRVI Stock Risks: Maravai Lifesciences Holdings, Inc.. Investment Risks
- Severe revenue contraction of 28.3% YoY signals fundamental business deterioration or significant market share loss
- Negative operating margin (-3.3%) and net margin (-5.7%) demonstrate company cannot achieve profitability from core operations
- Elevated debt of $241M with negative interest coverage ratio (-0.1x) creates solvency risk; operating cash flow insufficient to service debt
- Sustained revenue contraction and weak 18.3% gross margin
- Large operating losses and negative FCF indicating ongoing cash burn
- Leverage with negative interest coverage increases refinancing/dilution risk
Key Metrics to Watch
- Revenue trend - stabilization or further decline will determine cash burn trajectory and distress timeline
- Operating margin path to breakeven - critical indicator of operational turnaround viability
- Free cash flow generation relative to debt service - cash burn rate will determine duration of available runway
- Gross margin trajectory
- Operating cash flow turning positive
Maravai Lifesciences Holdings, Inc.. (MRVI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.91x current ratio provides a solid financial cushion.
MRVI Profit Margin, ROE & Profitability Analysis
MRVI vs Healthcare Sector: How Maravai Lifesciences Holdings, Inc.. Compares
How Maravai Lifesciences Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Maravai Lifesciences Holdings, Inc.. Stock Overvalued? MRVI Valuation Analysis 2026
Based on fundamental analysis, Maravai Lifesciences Holdings, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Maravai Lifesciences Holdings, Inc.. Balance Sheet: MRVI Debt, Cash & Liquidity
MRVI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Maravai Lifesciences Holdings, Inc..'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-0.90 indicates the company is currently unprofitable.
MRVI Revenue Growth, EPS Growth & YoY Performance
MRVI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $46.9M | -$3.7M | $-0.02 |
| Q3 2025 | $41.6M | -$25.6M | $-0.18 |
| Q2 2025 | $47.4M | -$9.8M | $-0.07 |
| Q1 2025 | $46.9M | -$12.1M | $-0.09 |
| Q3 2024 | $65.2M | -$6.5M | $-0.05 |
| Q2 2024 | $68.9M | -$6.5M | $-0.05 |
| Q1 2024 | $64.2M | -$67.0K | $0.00 |
| Q3 2023 | $66.9M | -$6.5M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Maravai Lifesciences Holdings, Inc.. Dividends, Buybacks & Capital Allocation
MRVI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Maravai Lifesciences Holdings, Inc.. (CIK: 0001823239)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRVI
What is the AI rating for MRVI?
Maravai Lifesciences Holdings, Inc.. (MRVI) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRVI's key strengths?
Claude: Strong cash position of $165.9M provides buffer for operations and debt obligations. Excellent liquidity metrics with current ratio of 5.91x and quick ratio of 4.96x demonstrate ability to meet short-term obligations. ChatGPT: Ample liquidity with high current/quick ratios and $216.9M cash. Low capex requirements support flexibility.
What are the risks of investing in MRVI?
Claude: Severe revenue contraction of 28.3% YoY signals fundamental business deterioration or significant market share loss. Negative operating margin (-3.3%) and net margin (-5.7%) demonstrate company cannot achieve profitability from core operations. ChatGPT: Sustained revenue contraction and weak 18.3% gross margin. Large operating losses and negative FCF indicating ongoing cash burn.
What is MRVI's revenue and growth?
Maravai Lifesciences Holdings, Inc.. reported revenue of $65.8M.
Does MRVI pay dividends?
Maravai Lifesciences Holdings, Inc.. does not currently pay dividends.
Where can I find MRVI SEC filings?
Official SEC filings for Maravai Lifesciences Holdings, Inc.. (CIK: 0001823239) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRVI's EPS?
Maravai Lifesciences Holdings, Inc.. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRVI a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Maravai Lifesciences Holdings, Inc.. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRVI stock overvalued or undervalued?
Valuation metrics for MRVI: ROE of -1.8% (sector avg: 15%), net margin of -5.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRVI stock in 2026?
Our dual AI analysis gives Maravai Lifesciences Holdings, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRVI's free cash flow?
Maravai Lifesciences Holdings, Inc..'s operating cash flow is $8.7M, with capital expenditures of $4.4M. FCF margin is 6.4%.
How does MRVI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.7% (avg: 12%), ROE -1.8% (avg: 15%), current ratio 5.91 (avg: 2).